<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">prmed</journal-id><journal-title-group><journal-title xml:lang="ru">Первичная медико-санитарная помощь</journal-title><trans-title-group xml:lang="en"><trans-title>Primary Health Care (Russian Federation)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">3034-4123</issn><issn pub-type="epub">3034-4565</issn><publisher><publisher-name>LTD "Silicea-Poligraf"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/3034-4123-2025-60</article-id><article-id custom-type="edn" pub-id-type="custom">WLJISU</article-id><article-id custom-type="elpub" pub-id-type="custom">prmed-60</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РАЗВИТИЕ МЕТОДОВ ДИАГНОСТИКИ И ЛЕЧЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>DEVELOPMENT OF DIAGNOSTIC AND TREATMENT METHODS</subject></subj-group></article-categories><title-group><article-title>Многогранность аутоиммунной патологии в аспекте воспалительных заболеваний кишечника. Клинический случай</article-title><trans-title-group xml:lang="en"><trans-title>The versatility of autoimmune pathology in inflammatory bowel diseases. A case report</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6151-2021</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бакулин</surname><given-names>И. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Bakulin</surname><given-names>I. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бакулин Игорь Геннадьевич — д.м.н., профессор, директор Института терапии, зав. кафедрой пропедевтики внутренних болезней, гастроэнтерологии и диетологии </p><p>ул. Кирочная, д. 41, г. Санкт-Петербург, 191015</p></bio><bio xml:lang="en"><p>Igor G. Bakulin</p><p>Kirochnaya str., 41, St. Petersburg, 191015</p></bio><email xlink:type="simple">igor.bakulin@szgmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4719-3973</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Акишина</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Akishina</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Акишина Юлия Андреевна  — ординатор кафедры пропедевтики внутренних  болезней,  гастроэнтерологии  и  диетологии </p><p>ул. Кирочная, д. 41, г. Санкт-Петербург, 191015</p></bio><bio xml:lang="en"><p>Yulia A. Akishina</p><p>Kirochnaya str., 41, St. Petersburg, 191015</p></bio><email xlink:type="simple">akishina220500@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО "Северо-Западный государственный медицинский университет им. И. И. Мечникова" Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Mechnikov North-West State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>18</day><month>10</month><year>2025</year></pub-date><volume>2</volume><issue>3</issue><fpage>13</fpage><lpage>20</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бакулин И.Г., Акишина Ю.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Бакулин И.Г., Акишина Ю.А.</copyright-holder><copyright-holder xml:lang="en">Bakulin I.G., Akishina Y.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://prmed.elpub.ru/jour/article/view/60">https://prmed.elpub.ru/jour/article/view/60</self-uri><abstract><p>Мультисистемность — одна из определяющих характеристик воспалительных заболеваний кишечника (ВЗК), которая рассматривается как предиктор неблагоприятного течения последних. Европейская организация по изучению болезни Крона и язвенного колита (ЯК) (ECCO) определяет внекишечные проявления (ВКП) как воспалительные патологические состояния у пациента с ВЗК, локализующиеся вне желудочно-кишечного тракта, патогенез которых либо зависит от экспансии/транслокации иммунных реакций, либо является независимым воспалительным событием, индуцированным ВЗК, либо имеет общую предрасположенность, определяемую факторами окружающей среды или наследственностью. Публикации ряда авторов свидетельствуют о встречаемости внекишечных проявлений в 50-60% случаев. В представленной работе описан клинический случай анкилозирующего спондилита (АС), HLAB27-позитивного, установленного до верификации диагноза ЯК, с последующим развитием хронического идиопатического панкреатита. В дебюте определялись высокие уровни острофазовых показателей, МР-признаки активного двустороннего сакроилиита III стадии и спондилитов всех поясничных позвонков; инициирована терапия сульфасалазином. В дальнейшем, с учетом отсутствия периферических проявлений АС, принято решение об инициации терапии упадацитинибом 15 мг/сут. Спустя несколько лет верифицирован диагноз ЯК, в связи с чем, увеличена доза упадацитиниба до 30 мг/сут., что обеспечило контроль течения АС и клинико-эндоскопическую ремиссию ЯК. Позже, в связи с абдоминальным болевым синдромом, выполнена мультиспиральная компьютерная томография органов брюшной полости — картина хронического кальцифицирующего панкреатита. В анамнезе отсутствуют употребление алкоголя и табакокурение. Лабораторно не выявлены гипертриглицеридемия, повышение IgG, антинуклеарные антитела. Специфических для аутоиммунного панкреатита КТпризнаков и гистологических находок не выявлено. Вышеупомянутый диагноз маловероятен, однако полностью не исключен в связи с отсутствием всех диагностических критериев, включая IgG4. Таким образом, при наличии настороженности в отношении иммуно-опосредованной патологии, повышается вероятность прецизионной диагностики как ВЗК, так и проявлений за пределами желудочно-кишечного тракта, что обеспечивает выбор эффективной таргетной терапии.</p></abstract><trans-abstract xml:lang="en"><p>Multisystem nature is characteristic for inflammatory bowel diseases (IBD), which is considered a predictor of unfavorable course. According to the European Crohn’s and Colitis Organisation (ECCO) extraintestinal manifestations (EIMs) are defined as "an inflammatory pathology in a patient with IBD that is located outside the gut whose pathogenesis is either dependent on extension/translocation of immune responses from the intestine, or is an independent inflammatory event perpetuated by IBD or that shares a common environmental or genetic predisposition with IBD". Data from several studies indicate that EIMs may affect 50-60% of patients. This report describes a case of HLA-B27-positive ankylosing spondylitis (AS) diagnosed prior to the confirmation of ulcerative colitis (UC) with subsequent development of idiopathic chronic pancreatitis. At onset, elevated acutephase reactants were revealed. MRI demonstrated active bilateral stage III sacroiliitis and active spondylitis of all lumbar vertebrae. Sulfasalazine was initiated. Subsequently given the absence of peripheral manifestations of AS, a decision to initiate therapy with upadacitinib 15 mg daily was made. Several years later a diagnosis of UC was established. Consequently, the upadacitinib dose was increased to 30 mg daily, achieving control of AS and clinical and endoscopic remission of UC. Later, contrast-enhanced abdominal computed tomography (CT) was performed due to abdominal pain. Chronic calcific pancreatitis was revealed. The patient's history of alcohol and smoking was negative. Laboratory investigations ruled out hypertriglyceridemia, elevated IgG levels, antinuclear antibodies. There were no autoimmune pancreatitis-specific CT features and histopathological findings. While the autoimmune pancreatitis is considered unlikely, it cannot be definitively ruled out due to the absence of all diagnostic criteria, including IgG4 subclass evaluation. Therefore, maintaining a high level of suspicion for immune-mediated pathology increases the chances of an accurate diagnosis for both IBD and EIMs. This facilitates the selection of effective targeted therapy.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>внекишечные проявления воспалительных заболеваний кишечника</kwd><kwd>анкилозирующий спондилит</kwd><kwd>идиопатический панкреатит</kwd><kwd>аутоиммунный панкреатит</kwd><kwd>таргетная иммуносупрессивная терапия</kwd><kwd>HLA-B27</kwd></kwd-group><kwd-group xml:lang="en"><kwd>extraintestinal manifestations of inflammatory bowel disease</kwd><kwd>ankylosing spondylitis</kwd><kwd>idiopathic pancreatitis</kwd><kwd>autoimmune pancreatitis</kwd><kwd>targeted immunosuppressive therapy</kwd><kwd>HLA-B27</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Hedin CRH, Vavricka SR, Stagg AJ, et al. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. J Crohns Colitis. 2019;13:541-54. doi:10.1093/ecco-jcc/jjy191.</mixed-citation><mixed-citation xml:lang="en">Hedin CRH, Vavricka SR, Stagg AJ, et al. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. J Crohns Colitis. 2019;13:541-54. doi:10.1093/ecco-jcc/jjy191.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rogler G, Singh A, Kavanaugh A, et al. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology. 2021;161(4):1118-32. doi:10.1053/j.gastro.2021.07.042.</mixed-citation><mixed-citation xml:lang="en">Rogler G, Singh A, Kavanaugh A, et al. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology. 2021;161(4):1118-32. doi:10.1053/j.gastro.2021.07.042.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Vavricka SR, Rogler G, Gantenbein C, et al. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis. 2015;21(8):1794-800. doi:10.1097/MIB.0000000000000429.</mixed-citation><mixed-citation xml:lang="en">Vavricka SR, Rogler G, Gantenbein C, et al. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis. 2015;21(8):1794-800. doi:10.1097/MIB.0000000000000429.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106(1):110-9. doi:10.1038/ajg.2010.343.</mixed-citation><mixed-citation xml:lang="en">Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106(1):110-9. doi:10.1038/ajg.2010.343.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Malik TF, Aurelio DM. Extraintestinal Manifestations of Inflammatory Bowel Disease. 2023 Mar 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.</mixed-citation><mixed-citation xml:lang="en">Malik TF, Aurelio DM. Extraintestinal Manifestations of Inflammatory Bowel Disease. 2023 Mar 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Broomé U, Bergquist A.Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis. 2006;26(1):31-41. doi:10.1055/s-2006-933561.</mixed-citation><mixed-citation xml:lang="en">Broomé U, Bergquist A.Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis. 2006;26(1):31-41. doi:10.1055/s-2006-933561.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 200511(46):7227-36. doi:10.3748/wjg.v11.i46.7227.</mixed-citation><mixed-citation xml:lang="en">Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 200511(46):7227-36. doi:10.3748/wjg.v11.i46.7227.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Vavricka SR, Schoepfer A, Scharl M, et al. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21(8):1982-92. doi:10.1097/MIB.0000000000000392.</mixed-citation><mixed-citation xml:lang="en">Vavricka SR, Schoepfer A, Scharl M, et al. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21(8):1982-92. doi:10.1097/MIB.0000000000000392.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kilic Y, Kamal S, Jaffar F, et al. Prevalence of Extraintestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2024;30(2):230-9. doi:10.1093/ibd/izad061.</mixed-citation><mixed-citation xml:lang="en">Kilic Y, Kamal S, Jaffar F, et al. Prevalence of Extraintestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2024;30(2):230-9. doi:10.1093/ibd/izad061.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Бакулин И.Г., Жигалова Т.Н., Латария Э.Л. и др. Опыт внедрения Федерального регистра пациентов с воспалительными заболеваниями кишечника в Санкт-Петербурге. Фарматека. 2017;(S5):56-9. EDN: ZXAAYR.</mixed-citation><mixed-citation xml:lang="en">Bakulin IG, Zhigalova TN, Lataria EL, et al. Experience of implementing the Federal Register of patients with inflammatory bowel diseases in St.Petersburg. Farmateka. 2017;(S5):56-9. (In Russ.) EDN: ZXAAYR.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Бакулин И.Г., Скалинская М.И., Сказываева Е.В. Северо-Западный регистр пациентов с воспалительными заболеваниями кишечника: достижения и уроки. Колопроктология. 2022;21(1):37-49. doi:10.33878/2073-7556-2022-21-1-37-49.</mixed-citation><mixed-citation xml:lang="en">Bakulin IG, Skalinskaya MI, Skazyvaeva EV. North-Western register of patients with inflammatory bowel disease: achievements and lessons learned. Koloproktologia. 2022;21(1):37-49. (In Russ.). doi:10.33878/2073-7556-2022-21-1-37-49.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Breban M, Tap J, Leboime A, et al. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis. 2017;76(9):1614-22. doi:10.1136/annrheumdis-2016-211064.</mixed-citation><mixed-citation xml:lang="en">Breban M, Tap J, Leboime A, et al. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis. 2017;76(9):1614-22. doi:10.1136/annrheumdis-2016-211064.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Karreman MC, Luime JJ, Hazes JMW, et al. The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis. 2017;11(5):631-42. doi:10.1093/ecco-jcc/jjw199.</mixed-citation><mixed-citation xml:lang="en">Karreman MC, Luime JJ, Hazes JMW, et al. The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis. 2017;11(5):631-42. doi:10.1093/ecco-jcc/jjw199.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Evans J, Sapsford M, McDonald S, et al. Prevalence of axial spondyloarthritis in patients with inflammatory bowel disease using cross-sectional imaging: a systematic literature review. Ther Adv Musculoskelet Dis. 2021;13:1759720X21996973. doi:10.1177/1759720X21996973.</mixed-citation><mixed-citation xml:lang="en">Evans J, Sapsford M, McDonald S, et al. Prevalence of axial spondyloarthritis in patients with inflammatory bowel disease using cross-sectional imaging: a systematic literature review. Ther Adv Musculoskelet Dis. 2021;13:1759720X21996973. doi:10.1177/1759720X21996973.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Braun J, Sieper J. Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis. RMD Open. 2023;9(3):e003102. doi:10.1136/rmdopen-2023-003102.</mixed-citation><mixed-citation xml:lang="en">Braun J, Sieper J. Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis. RMD Open. 2023;9(3):e003102. doi:10.1136/rmdopen-2023-003102.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Arvikar SL, Fisher MC. Inflammatory bowel disease associated arthropathy. Curr Rev Musculoskelet Med. 2011;4:123-31. doi:10.1007/s12178-011-9085-8.</mixed-citation><mixed-citation xml:lang="en">Arvikar SL, Fisher MC. Inflammatory bowel disease associated arthropathy. Curr Rev Musculoskelet Med. 2011;4:123-31. doi:10.1007/s12178-011-9085-8.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180(6):2359-64. doi:10.1084/jem.180.6.2359.</mixed-citation><mixed-citation xml:lang="en">Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180(6):2359-64. doi:10.1084/jem.180.6.2359.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Tito RY, Cypers H, Joossens M, et al. Brief Report: Dialister as a Microbial Marker of Disease Activity in Spondyloarthritis. Arthritis Rheumatol. 2017;69:114-21. doi:10.1136/annrheumdis-2016-211064.</mixed-citation><mixed-citation xml:lang="en">Tito RY, Cypers H, Joossens M, et al. Brief Report: Dialister as a Microbial Marker of Disease Activity in Spondyloarthritis. Arthritis Rheumatol. 2017;69:114-21. doi:10.1136/annrheumdis-2016-211064.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of Upadacitinib in a Randomized Trial of Patients with Active Ulcerative Colitis. Gastroenterology. 2020;158:2139-49. e14. doi:10.1053/j.gastro.2020.02.030.</mixed-citation><mixed-citation xml:lang="en">Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of Upadacitinib in a Randomized Trial of Patients with Active Ulcerative Colitis. Gastroenterology. 2020;158:2139-49. e14. doi:10.1053/j.gastro.2020.02.030.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Sandborn WJ, Feagan BG, Loftus EV Jr, et al. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients with Crohn’s Disease. Gastroenterology. 2020; 158:2123-38.e8. doi:10.1053/j.gastro.2020.01.047.</mixed-citation><mixed-citation xml:lang="en">Sandborn WJ, Feagan BG, Loftus EV Jr, et al. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients with Crohn’s Disease. Gastroenterology. 2020; 158:2123-38.e8. doi:10.1053/j.gastro.2020.01.047.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Guillo L, D’Amico F, Danese S, et al. Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review. J Crohns Colitis. 2021;15:1236-43. doi:10.1093/ecco-jcc/jjaa260.</mixed-citation><mixed-citation xml:lang="en">Guillo L, D’Amico F, Danese S, et al. Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review. J Crohns Colitis. 2021;15:1236-43. doi:10.1093/ecco-jcc/jjaa260.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Lim J, Rezaie A. Irritable Bowel Syndrome-Like Symptoms in Quiescent Inflammatory Bowel Disease: A Practical Approach to Diagnosis and Treatment of Organic Causes. Dig Dis Sci. 2023;68(11):4081-97. doi:10.1007/s10620-023-08095-w.</mixed-citation><mixed-citation xml:lang="en">Lim J, Rezaie A. Irritable Bowel Syndrome-Like Symptoms in Quiescent Inflammatory Bowel Disease: A Practical Approach to Diagnosis and Treatment of Organic Causes. Dig Dis Sci. 2023;68(11):4081-97. doi:10.1007/s10620-023-08095-w.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Fousekis FS, Theopistos VI, Katsanos KH, et al. Pancreatic involvement in inflammatory bowel disease: a review. J Clin Med Res. 2018;10:743-51. doi:10.14740/jocmr3561w.</mixed-citation><mixed-citation xml:lang="en">Fousekis FS, Theopistos VI, Katsanos KH, et al. Pancreatic involvement in inflammatory bowel disease: a review. J Clin Med Res. 2018;10:743-51. doi:10.14740/jocmr3561w.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Lohr JM, Dominguez-Munoz E, Rosendahl J, et al. United European gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU) United Eur Gastroenterol J. 2017;5:153-99. doi:10.1177/2050640616684695.</mixed-citation><mixed-citation xml:lang="en">Lohr JM, Dominguez-Munoz E, Rosendahl J, et al. United European gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU) United Eur Gastroenterol J. 2017;5:153-99. doi:10.1177/2050640616684695.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Бордин Д.С., Кучерявый Ю.А., Кирюкова М.А. Обновленная этиологическая классификация панкреатитов TIGAR-O (версия 2): адаптация для российской клинической практики. Альманах клинической медицины. 2020;48(6):349-63. doi:10.18786/2072-0505-2020-48-062.</mixed-citation><mixed-citation xml:lang="en">Bordin DS, Kucheryavyy YA, Kiryukova MA. The revised pancreatitis etiologybased classification system TIGAR-O, version 2: adaptation for the Russian clinical practice. Almanac of Clinical Medicine. 2020;48(6):349-63. (In Russ.) doi:10.18786/2072-0505-2020-48-062.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
